Equities Analysts Offer Predictions for SLNO Q3 Earnings

Key Points

• HC Wainwright trimmed Q3 2026 EPS to $1.15 (from $1.24) and cut its price target to $100, but kept a "Buy" rating and provided multi-quarter 2026–2027 forecasts that project material earnings growth by 2027.
• Soleno's Q4 results beat expectations, with EPS of $0.80 versus a $0.64 consensus and revenue of $91.7M versus $88.6M, bolstering near-term confidence in sales and cash generation.
• Street sentiment remains broadly positive, with an average analyst rating of "Moderate Buy" and an average target of $106.85, even as the stock trades around $38.57 (market cap ≈ $2.0B) and institutional ownership is very high (~97%).

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Soleno Therapeutics in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $1.15 per share for the quarter, down from their previous forecast of $1.24. HC Wainwright has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q4 2026 earnings at $1.56 EPS, FY2026 earnings at $4.65 EPS, Q1 2027 earnings at $1.58 EPS, Q2 2027 earnings at $1.78 EPS, Q3 2027 earnings at $1.96 EPS and Q4 2027 earnings at $2.18 EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million.

SLNO has been the subject of several other research reports. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research report on Tuesday, January 13th. TD Cowen lowered their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a research note on Monday, January 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company reduced their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an "overweight" rating for the company in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Soleno Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $106.85.

Soleno Therapeutics Stock Up 1.2%

SLNO opened at $38.57 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a 12 month low of $32.63 and a 12 month high of $90.32. The stock has a market capitalization of $1.99 billion, a P/E ratio of 167.70 and a beta of -3.16. The business has a 50 day simple moving average of $41.77 and a 200-day simple moving average of $52.42.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Soleno Therapeutics in the fourth quarter valued at about $38,000. Seven Fleet Capital Management LP acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth approximately $6,023,000. Virtu Financial LLC purchased a new stake in Soleno Therapeutics in the 4th quarter valued at approximately $1,059,000. Empowered Funds LLC purchased a new stake in Soleno Therapeutics in the 4th quarter valued at approximately $69,000. Finally, KVP Capital Advisors LP acquired a new stake in Soleno Therapeutics during the 4th quarter valued at $2,764,000. Institutional investors and hedge funds own 97.42% of the company's stock.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Q4 results topped expectations: revenue of $91.7M and GAAP EPS of $0.80 beat consensus, supporting near-term confidence in sales execution and cash generation. Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy
• Positive Sentiment: HC Wainwright continues to rate SLNO "Buy" and raised several near-term EPS forecasts (Q1 and Q2 2026) and a bullish FY2027 view (analyst models show material earnings growth by 2027), which supports upside versus current levels and reinforces analyst conviction into the story. Analyst Comments / Street Insider
• Neutral Sentiment: HC Wainwright published a detailed set of quarterly and annual forecasts for 2026–2027 (multiple Qs and FY lines); these create a clearer roadmap for future earnings but are model-driven and carry execution risk—useful for positioning but not guaranteed.
• Negative Sentiment: At the same time, HC Wainwright trimmed several 2026 estimates (notably Q3 & Q4 2026 and FY2026 modestly) and lowered its price target from $120 to $100 — a reduction in near-term modeled upside even though the firm remains constructive. Benzinga Coverage Street Insider Coverage

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.